| Item Type | Name |
|
Concept
|
Dermatologic Agents
|
|
Academic Article
|
Comparative tolerability of systemic treatments for plaque-type psoriasis.
|
|
Academic Article
|
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
|
|
Academic Article
|
Severe hidradenitis suppurativa treated with infliximab infusion.
|
|
Academic Article
|
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
|
|
Academic Article
|
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
|
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
|
|
Academic Article
|
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
|
|
Academic Article
|
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
|
|
Academic Article
|
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
|
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
|
|
Academic Article
|
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
|
|
Academic Article
|
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
|
|
Academic Article
|
Patient satisfaction and quality of life in psoriasis and psoriatic arthritis.
|
|
Academic Article
|
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
|
|
Academic Article
|
Translating the Science of Psoriasis.
|
|
Academic Article
|
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
|
|
Academic Article
|
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.
|
|
Academic Article
|
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
|
|
Academic Article
|
Systemics to topicals in psoriasis: the unfilled need.
|
|
Academic Article
|
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
|
|
Academic Article
|
Treating to Target-A Realistic Goal in Psoriasis?
|
|
Academic Article
|
The Evolving Landscape of Psoriasis Treatment.
|
|
Academic Article
|
Practical Strategies for Optimizing Management of Psoriasis.
|
|
Academic Article
|
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
|
|
Academic Article
|
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
|
|
Academic Article
|
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
|
|
Academic Article
|
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
|
|
Academic Article
|
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
|
|
Academic Article
|
IL-23 inhibitors for moderate-to-severe psoriasis.
|
|
Academic Article
|
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
|
|
Academic Article
|
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
|
|
Academic Article
|
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
|
|
Academic Article
|
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
|
|
Academic Article
|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
|
|
Academic Article
|
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
|
|
Academic Article
|
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
|
|
Academic Article
|
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
|